Introduction {#Sec1}
============

European data from 2001 to 2011 for hematopoietic stem cell transplantation (HSCT) show that the number of allogeneic HSCT doubled and the number of autologous HSCT increased by 32 %, with an ongoing constant increase of about 1100 autologous HSCT per year since 2001 \[[@CR1]\]. In Germany, similar increases were observed, in allogeneic HSCT 107 % and in autologous HSCT 37.9 % from 2001 to 2011 (first transplantations only) \[[@CR2]\]. In the course of this development, pre-transplant regimens for both myelogenous and lymphoid malignancies are continuously refined with the aim to reduce toxicity and to improve survival \[[@CR3]--[@CR5]\]. This process resulted also in a continuous replacement of total body irradiation during conditioning therapy for HSCT by the bifunctional DNA alkylating myelotoxic agent busulfan (BU) \[[@CR4], [@CR6], [@CR5]\]. The availability of the intravenous (IV) formulation of BU plays an important role in the development of optimized treatment plans \[[@CR4]--[@CR6], [@CR3]\].

Oral intake of BU is problematic due to the large number of tablets, which are required to achieve recommended BU doses \[[@CR7]\]. Oral BU intake causes severe irritation of the gastric mucosa accompanied by nausea and vomiting. Intestinal absorption of the drug is highly variable, and bioavailability is largely unpredictable. Wide inter- and intra-patient variability in BU pharmacokinetics is therefore a concern \[[@CR5], [@CR7]\]. The therapeutic range of BU is narrow, and the total exposure to BU seems to be critical for graft rejection and survival \[[@CR5], [@CR6], [@CR3]\]. Oral mucositis (OM) and its consequences like severe pain, problems of food intake, and rising risk of infection are observed more frequently with the oral preparation of BU (O-BU). The life-threatening complication of hepatic sinusoidal obstruction syndrome (SOS) is a major complication of BU. In clinical trials, it could be demonstrated that these adverse events are reduced by use of the IV formulation \[[@CR8]--[@CR14]\].

The advantageous IV formulation of BU is associated with incremental costs compared to O-BU. In Germany, an extra budget, a so-called "Zusatzentgelt" ZE 79, is paid for the use of IV-BU for HSCT recipients below the age of 15 years \[[@CR15]\]. So far, IV-BU administration in adult patients is not covered by a "Zusatzentgelt." Additional costs associated with IV-BU have to be covered by budget reimbursed through the specific diagnosis-related groups (DRG). In 2012, 767 adult German patients, 12.3 % of all HSCT, received BU for conditioning prior to HSCT. Replacing O-BU with IV-BU would result in an increase of total drug costs by approximately € 2.5 to € 3 million. However, from an economic perspective, it might be misleading to consider isolated drug costs only. The impact of total cost in comparison to the previous standard of care has to be evaluated to determine the economic value. New therapies, which are expensive, might be adopted, because they result in essentially the same net total costs as the comparator due to a reduction in costs for the treatment of adverse events. Budget-impact models (BIMs) can be used to calculate "the net cumulative cost of treatment with a particular therapy for a given number of patients in a specific population" \[[@CR16], [@CR17]\]. BIMs might give advice to the provider during decision making.

In the following, the development of a BIM is described, analyzing net cumulative costs in adult HSCT recipients from a German providers' perspective comparing the IV formulation of BU to the oral preparation.

Methods {#Sec2}
=======

Budget-impact model (BIM) {#Sec3}
-------------------------

Model calculations are recommended to be used when the number of data regarding treatment outcomes and treatment patterns is limited. A decision tree model was developed with Microsoft Excel 2010® to evaluate the budget impact of IV-BU versus O-BU during conditioning for HSCT from a German health care providers' perspective. Drug costs, as well as frequency and treatment costs of drug-related side effects and adverse reactions, were considered (Fig. [1](#Fig1){ref-type="fig"}).Fig. 1Decision tree. *HSCT* hematopoietic stem cell transplantation, *BU* busulfan, *IV* intravenous, *O* oral, *OM* oral mucositis, *SOS* hepatic sinusoidal obstruction syndrome, *MOF* multiorgan failure

Model input {#Sec4}
-----------

PubMED was searched for data comparing IV-BU versus O-BU regarding risks for OM, infection with OM and SOS with or without multiorgan failure (MOF). The following searches were conducted: ("Busulfan"\[Mesh\]) and "Administration, Intravenous"\[Mesh\]; ("Economics"\[Mesh\]) and "Stomatitis"\[Mesh\]; ("Hepatic Veno-Occlusive Disease"\[Mesh\]) and "Busulfan"\[Mesh\]; "Busulfan"\[Mesh\] review, last 10 years; "Hepatic Veno-Occlusive Disease"\[Mesh\] review, last 10 years. In addition, free search terms, e.g., "oral mucositis" and "intravenous busulfan" were applied. Citations of identified journal articles were searched for further relevant publications. Desktop researches were conducted. The model input consists of event rates and cost data. Event rates for the base case and a short characterization of the study populations are given in Table [1](#Tab1){ref-type="table"} \[[@CR10], [@CR11], [@CR13], [@CR14], [@CR18], [@CR19]\]. Mild SOS was not considered. Reliable treatment cost data and event rates are lacking for mild SOS due to generally spontaneous cessation of the disease. German cost data shown in Table [2](#Tab2){ref-type="table"} were taken from literature \[[@CR20]--[@CR25]\] and tariff lists, except for cost of OM grade 1--2. Due to a lack of published cost data, average costs of OM grade 1--2 were determined based on resource use (time of physicians and nurses, rinsing solutions, local anesthetics, antimycotics, morphine gel) estimated by clinical experts and trained nurses.Table 1Model input: event rates base caseParameterEvent rate \[%\]Study populationSourceO-BUIV-BURisk of oral mucositis (OM) Patients without OM44.1897.5Allogeneic HSCT; conditioning: BU/cyclophosphamide; 93 patients O-BU compared to 42 patients IV-BUSobecks et al. (2012) \[[@CR14]\] Patients with OM Grade 1--231.40 Patients with OM Grade 3--424.422.5Risk of documented infection with OM Patients with infection without OM18.12599 Cancer patients with chemotherapy-induced myelosuppressionElting et al. (2003) \[[@CR19]\] Patients with infection with OM Grade 1--218.98 Patients with infection with OM Grade 3--435.71Risk of hepatic sinusoidal obstruction syndrome (SOS) Patients with moderate SOS16.6714.55Allogeneic HSCT; conditioning: BU/cyclophosphamide; 186 patients O-BU compared to 55 patients IV-BULee et al. (2005) \[[@CR13]\] Patients with severe SOS5.910 Patients with severe SOS with MOF4.980Frequency to develop fatal multiorgan failure (MOF) with severe SOS84.3Meta-analysis of published studies from 1979 to October 2007Coppell et al. (2010) \[[@CR18]\]Table 2Model input: costParameterCost \[€\]SourceDrug costs O-BU 1 mg1.18Wholesale price 2013 exclusive of VAT \[[@CR25]\] IV-BU 1 mg5.51Wholesale price 2013 exclusive of VAT \[[@CR25]\] Defibrotide 1 mg0.82German NUB Antrag 2012/2013 \[[@CR24]\]Total costs for adverse events OM Grade 1--250Own estimation based on clinical experts OM Grade 3--4312Banz et al.(2011) \[[@CR20]\] Infection7 093Paessens et al. (2011) \[[@CR22]\] Moderate SOS21 398^a^ Severe SOS35 663^a^ Severe SOS with MOF61 109^b^*VAT* value-added tax^a^Costs of SOS were estimated calculating the costs of treatment with defibrotide according to the German NUB Antrag (new examination and treatment methods application) 2012/2013 assuming dosing according to Richardson et al. \[[@CR23], [@CR24]\]. Average duration of moderate and severe SOS (15 and 25 days, respectively) were taken from the study of Lee et al. \[[@CR13]\]^b^Cost of MOF was estimated by addition of German costs for fatal sepsis to costs of severe SOS \[[@CR21]\]

Assumption {#Sec5}
----------

Due to a lack of German cost data on SOS or length of hospital stay with SOS in Germany, it was assumed that cost of SOS is represented by treatment with defibrotide as a major cost component. Defibrotide is recommended for treatment of SOS \[[@CR26]\].

Base case {#Sec6}
---------

Calculations in the model were started with a base case. Adult patient weighed 70 kg was conditioned prior to HSCT with 1.0 mg/kg O-BU or 0.8 mg/kg IV-BU four times daily for 4 days. The event rates of OM and SOS for the base case were taken from the studies of Sobecks et al. \[[@CR14]\] and Lee et al. \[[@CR13]\] (Table [1](#Tab1){ref-type="table"}). Both are more recent studies with large study populations concerning allogeneic HSCT and conditioning with BU and cyclophosphamide.

Sensitivity analyses {#Sec7}
--------------------

Sensitivity analyses were conducted in several ways. (1) Event rates of OM from the study of Ferrara et al. \[[@CR10]\] and event rates of SOS from the study of Kashyap et al. \[[@CR11]\] were inserted in the model (Table [3](#Tab3){ref-type="table"}). (2) Calculations were conducted considering SOS only without costs for OM and infection with OM. (3) Minus and plus 25 % of risks of all adverse events for O-BU and IV-BU were applied. (4) A worst case scenario was calculated assuming minus 25 % of risks of all adverse events for O-BU and plus 25 % for IV-BU \[[@CR27]\].Table 3Model input: event rates sensitivity analysesParameterEvent rate \[%\]Study populationSourceO-BUIV-BURisk of oral mucositis (OM) Patients without OM772Autologous HSCT; conditioning: BU/idarubicin; 30 patients O-BU compared to 25 patients IV-BUFerrara et al. (2009) \[[@CR10]\] Patients with OM Grade 1--21316 Patients with OM Grade 3--48012Risk of hepatic sinusoidal obstruction syndrome (SOS) Patients with moderate SOS13.334.92Allogeneic HSCT; conditioning: BU/cyclophosphamide; 30 patients O-BU compared to 61 patients IV-BUKashyap et al. (2002) \[[@CR11]\] Patients with severe SOS6.673.28 Patients with severe SOS with MOF5.622.77

Model output {#Sec8}
------------

Model output was expressed as total costs of adverse events with O-BU, total costs of adverse events with IV-BU, total costs of adverse events with O-BU plus drug costs of O-BU, and total costs of adverse events with IV-BU plus drug costs of IV-BU. Results were presented as follows: cost savings or additional costs with IV-BU for ten patients; total costs for groups of ten patients receiving O-BU or IV-BU, respectively. In worst case scenarios assuming minus 25 % of risks of all adverse events for O-BU and plus 25 % for IV-BU, potentially arising additional costs per ten patients with IV-BU were calculated. All calculations were done using the event rates from the different studies available. All adverse events were considered, as well as drug costs for O-BU and IV-BU, if not otherwise stated.

Number needed to treat {#Sec9}
----------------------

The number needed to treat (NNT) to prevent one additional severe SOS was calculated using the base case event rates from the study of Lee et al. (Table [1](#Tab1){ref-type="table"}) \[[@CR13]\]. A range was given: lower border is a high hypothetical case of occurrence of SOS with ten times higher event rates; upper border is a low hypothetical case of occurrence of SOS with ten times lower event rates \[[@CR28]\].

Results {#Sec10}
=======

Drug costs considering ten patients for conditioning with O-BU are €13,160 and with IV-BU €49,380 \[[@CR25]\].

Results for base case calculations and sensitivity analyses are displayed in Fig. [2](#Fig2){ref-type="fig"}. All calculations ended up in cost savings with IV-BU.Fig. 2Average cost savings per ten patients with IV-BU. Average cost savings per ten patients with IV-BU are shown for the base case. For the sensitivity analyses, event rates of OM from the study of Ferrara et al. \[[@CR10]\] and event rates of SOS from the study of Kashyap et al. \[[@CR11]\] were inserted in the model. S = Sobecks et al. \[[@CR14]\], E = Elting et al. \[[@CR19]\], L = Lee et al. \[[@CR19]\], K = Kashyap et al. \[[@CR11]\], F = Ferrara et al. \[[@CR10]\]

Considering SOS only as a relevant adverse event and disregarding OM and infection with OM, cost savings in the model are approximately €2070 per ten patients applying the data of Lee et al. \[[@CR13]\] and €1140 per ten patients with the data of Kashyap et al. \[[@CR11]\].

In the base case, total costs of adverse events were €86,434 with O-BU and €44,376 with IV-BU for ten patients each. Total costs of adverse events with O-BU plus drug costs of O-BU were €99,594 and with IV-BU plus drug costs of IV-BU €93,755 for ten patients each (Fig. [3a](#Fig3){ref-type="fig"}, base case: event rates from Sobecks/Elting/Lee et al.). Cost of adverse events plus drug costs of BU using the different study data available are shown in Fig. [3b--d](#Fig3){ref-type="fig"}. The development of total costs in sensitivity analyses assuming either minus 25 % (minimum) or plus 25 % (maximum) of risks of all adverse events for O-BU and IV-BU for the base case and all different study data available is included in Fig. [3a--d](#Fig3){ref-type="fig"}.Fig. 3Sensitivity analyses: minus and plus 25 % of risks of all adverse events for O-BU and IV-BU. Total costs of adverse events plus drug cost of BU are shown for groups of ten patients each with either O-BU or IV-BU. Minus 25 % (minimum) and plus 25 % (maximum) of risks of all adverse events for O-BU and IV-BU were applied on the event rates of all available studies on OM, infection with OM, and SOS \[[@CR10], [@CR11], [@CR13], [@CR14], [@CR19]\]. S = Sobecks et al. \[[@CR14]\], E = Elting et al. \[[@CR19]\], L = Lee et al. \[[@CR13]\], K = Kashyap et al. \[[@CR11]\], F = Ferrara et al. \[[@CR10]\], (min) = minimum, (max) = maximum

Calculating worst case scenarios assuming minus 25 % of risks of all adverse events for O-BU and plus 25 % for IV-BU results in additional costs with IV-BU of €27,570 per ten patients with the data of Sobecks et al. \[[@CR14]\] and Lee et al. \[[@CR13]\] (base case), €25,040 per ten patients with the data of Sobecks et al. \[[@CR14]\] and Kashyap et al. \[[@CR11]\], €24,970 per ten patients with the data of Ferrara et al. \[[@CR10]\] and Lee et al. \[[@CR13]\], €22,440 per ten patients with the data of Ferrara et al. \[[@CR10]\] and Kashyap et al. \[[@CR11]\]. Omitting the costs for OM and infection with OM in the worst case scenario leads to additional costs with IV-BU of €23,070 per ten patients using the data of Lee et al. \[[@CR13]\] for SOS and of €22,830 per ten patients using the data of Kashyap et al. \[[@CR11]\] for SOS.

The average NNT results in 17 patients needed to treat to prevent one case of severe SOS, with a range of 2 to 169 patients using high and low hypothetical cases of occurrence of SOS \[[@CR28]\].

Discussion {#Sec11}
==========

This is the first economic assessment of IV-BU compared to O-BU presented for Germany. Considering risks and treatment costs for OM, infection with OM and SOS, as well as drug costs, IV-BU is cost saving and therefore dominant compared to O-BU. IV-BU remains the dominant alternative, even if the study data used for the base case are replaced by other available study data or if solely the adverse event SOS is considered.

Two other economic models have been presented so far as conference abstracts comparing costs arising with O-BU compared to IV-BU taking only SOS into consideration. Based on US costs for SOS \[[@CR29]\], a French model calculated additional costs of €1605.4 per patient with IV-BU \[[@CR30]\]. A cost-effectiveness analysis from Mexico demonstrated that IV-BU was dominant over O-BU \[[@CR31]\]. Taking different event rates and different health care systems into consideration, a comparison with these studies is limited.

In sensitivity analyses, changes in total cost of adverse events calculating with plus and minus 25 % of all risks were chosen for the following reasons: the historical nature of the available study data leads to considerable uncertainties despite a similar trend regarding the favorable results with IV-BU. The cost components could not be based on up-to-date data of treatment patterns and resource use and were estimated in a most conservative way, e.g., not including costs of hospital stay for SOS. Therefore, it did not seem adequate to analyze the influence of individual parameters in this context of uncertainties of event rates and cost components. Worst case scenarios assuming minimal risks of adverse events for O-BU (−25 %) and maximal risks of adverse events for IV-BU (+25 %) result in additional costs for IV-BU amounting to a maximum of 56 % of the drug costs using base case data. These extra costs appear relatively modest in the context of HSCT \[[@CR32]\].

The average NNT with IV-BU is 17 patients to prevent one case of severe SOS. Regarding the total number of patients treated in Germany with BU for conditioning prior to HSCT, potentially up to 45 patients are spared severe SOS. In view of the considerable mortality of severe SOS after allogeneic HSCT, IV-BU appears highly favorable \[[@CR18]\].

If pharmacokinetic-directed high-dose BU is used, similar results can be achieved with O-BU and IV-BU. However, the data indicated a slightly improved 5-year overall survival with IV-BU compared to O-BU \[[@CR33]\]. A prospective cohort study comparing IV-BU with total body irradiation (TBI) used for conditioning prior to HSCT demonstrated non-inferiority of IV-BU. Two-year probabilities of survival were improved with IV-BU compared to TBI \[[@CR4]\]. An earlier study comparing O-BU with IV-BU during reduced intensity conditioning for allogeneic HSCT found lower incidence of acute graft-versus-host disease (GvHD) and early infectious complications leading to significantly improved overall survival with IV-BU \[[@CR34]\]. Further studies are required to understand the mechanisms by which IV-BU-based regimens result in superior survival outcomes and to evaluate possible influences on GvHD. Due to increasing rates of GvHD with increasing toxicity of the regimens preceding allogeneic HSCT, the advantages of IV-BU may be even more pronounced \[[@CR35]\]. In contrast to a cost-effectiveness analysis, a BIM does not consider differences in mortality rates of therapies, i.e., differences in life years gained \[[@CR32]\]. Improvements in quality of life, which are achieved by less and less severe OM during treatment with IV-BU compared to O-BU, are not reflected in the calculations.

There are some limitations concerning studies and cost data inserted in the model. The data used for the model comparing frequencies of adverse events with O-BU and IV-BU were from four retrospective clinical studies \[[@CR11], [@CR13], [@CR14], [@CR19]\] and one prospective and retrospective comparison \[[@CR10]\] with obviously heterogenous patient populations. In one study, the groups had variable use of methotrexate \[[@CR14]\]; in another study, patients with a different ethnic background as compared to German patients were investigated \[[@CR13]\], and another study comprised autologous HSCT instead of allogeneic HSCT and used an experimental drug combination of BU and idarubicin \[[@CR10]\]. The conclusions of the model had to be based exclusively on literature historical data due to lack of up-to-date evidence-based studies. Infection rates with OM were derived from a study on chemotherapy-induced OM in cancer patients, because comparative data on infections in patients with or without OM after HSCT were not available \[[@CR19]\]. Cost data for treatment of OM grade 3--4 and for treatment of infection were both from publications on cancer patients receiving chemotherapy \[[@CR20], [@CR22]\]. Published data on treatment costs of OM and infection of patients after allogeneic HSCT were not available and might differ in patients after chemotherapy due to potentially different severity and duration or different influence on length of hospital stay or readmission to the hospital. Estimations had also to be made for German cost data on SOS. Treatment costs of SOS were based on the assumption that defibrotide is a major cost component. This is a simplification of a probably much more complex issue. However again, German cost data on SOS or length of hospital stay with SOS in Germany were not available. Therefore, this estimation close to current clinical practice was chosen. Various approaches in the sensitivity analyses were used to account for these uncertainties. The applicability of this economic assessment of IV-BU compared to O-BU from a German providers' perspective to other countries is limited. The influence of IV-BU on costs may produce variable results as a function of differences in treatment patterns, costs, health care systems, and the country-specific type of health economic evaluation. However, the basic approach of our model calculations can be transferred to other countries using country-specific costs for treatment of adverse events and, if available, up-to-date study data comparing IV-BU with O-BU.

Conclusions {#Sec12}
===========

The presented budget-impact calculations (IV-BU compared to O-BU) from a German health care providers' perspective show cost savings in overall costs of HSCT. Sensitivity analyses result in moderate cost increase for IV-BU when calculating worst case scenarios. Based on model calculations, the use of IV-BU in adult patients undergoing HSCT seems to be reasonable. Contemporary real-life data on frequencies of OM and SOS in the course of HSCT with IV-BU compared to O-BU, up-to-date treatment patterns for OM and SOS, as well as resource use and costs of OM, SOS, and HSCT are needed to allow for further analyses.
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